AVR
Anteris Technologies Global Corp.
Medical - Devices
Market Cap$237M
5Y Perf.+17.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
AVR vs EW
Revenue, margins, valuation, and 5-year total return — side by side.
EW
Edwards Lifesciences Corporation
Medical - Devices
Market Cap$46.10B
5Y Perf.+8.0%
AVR vs EW — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AVR | EW |
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $237M | $46.10B |
| Revenue (TTM) | $2M | $6.07B |
| Net Income (TTM) | $-84M | $1.07B |
| Gross Margin | 67.9% | 78.1% |
| Operating Margin | -40.2% | 26.7% |
| Forward P/E | — | 26.6x |
| Total Debt | $1M | $705M |
| Cash & Equiv. | $70M | $2.94B |
AVR vs EW — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AVR
EW
| Stock | Dec 24 | May 26 | Return |
|---|---|---|---|
| Anteris Technologie… (AVR) | 100 | 117.9 | +17.9% |
| Edwards Lifescience… (EW) | 100 | 108.0 | +8.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AVR vs EW
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: EW leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Anteris Technologies Global Corp. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
AVR
Anteris Technologies Global Corp.
The Defensive Pick
AVR is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 2.14, Low D/E 2.2%, current ratio 4.51x
- +50.2% vs EW's +7.1%
Best for: sleep-well-at-night
EW
Edwards Lifesciences Corporation
The Income Pick
EW carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.64
- Rev growth 11.5%, EPS growth -73.7%, 3Y rev CAGR 4.1%
- 125.5% 10Y total return vs AVR's 17.5%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | EW | 11.5% revenue growth vs AVR's -1.2% |
| Quality / Margins | EW | 17.6% margin vs AVR's -39.4% |
| Stability / Safety | EW | Beta 0.64 vs AVR's 2.14 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | AVR | +50.2% vs EW's +7.1% |
| Efficiency (ROA) | EW | 8.0% ROA vs AVR's -442.1% |
AVR vs EW — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
AVR vs EW — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAVRLAGGINGEW
EWEdwards Lifesciences …
2leads
AVRAnteris Technologies …
2leads
6 Total Categories
CATEGORYLEADERvs EWMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
EW5/6
Valuation MetricsMultiples, price ratios, and targets
AVR2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
EW4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
AVR5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
EW leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
EW is the larger business by revenue, generating $6.1B annually — 2836.5x AVR's $2M. EW is the more profitable business, keeping 17.6% of every revenue dollar as net income compared to AVR's -39.4%. On growth, EW holds the edge at +13.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AVRAnteris Technolog… | EWEdwards Lifescien… |
|---|---|---|
| RevenueTrailing 12 months | $2M | $6.1B |
| EBITDAEarnings before interest/tax | -$84M | $1.8B |
| Net IncomeAfter-tax profit | -$84M | $1.1B |
| Free Cash FlowCash after capex | -$79M | $1.3B |
| Gross MarginGross profit ÷ Revenue | +67.9% | +78.1% |
| Operating MarginEBIT ÷ Revenue | -40.2% | +26.7% |
| Net MarginNet income ÷ Revenue | -39.4% | +17.6% |
| FCF MarginFCF ÷ Revenue | -37.1% | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -44.2% | +13.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -54.1% | -75.4% |
EW leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
AVR leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | AVRAnteris Technolog… | EWEdwards Lifescien… |
|---|---|---|
| Market CapShares × price | $237M | $46.1B |
| Enterprise ValueMkt cap + debt − cash | $168M | $43.9B |
| Trailing P/EPrice ÷ TTM EPS | -1.75x | 43.69x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 26.58x |
| PEG RatioP/E ÷ EPS growth rate | — | 6.17x |
| EV / EBITDAEnterprise value multiple | — | 24.47x |
| Price / SalesMarket cap ÷ Revenue | 87.79x | 7.60x |
| Price / BookPrice ÷ Book value/share | 2.13x | 4.53x |
| Price / FCFMarket cap ÷ FCF | — | 34.53x |
AVR leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
EW leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
EW delivers a 10.4% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $-25 for AVR. AVR carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to EW's 0.07x.
| Metric | AVRAnteris Technolog… | EWEdwards Lifescien… |
|---|---|---|
| ROE (TTM)Return on equity | -25.1% | +10.4% |
| ROA (TTM)Return on assets | -4.4% | +8.0% |
| ROICReturn on invested capital | — | +15.5% |
| ROCEReturn on capital employed | -183.9% | +14.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.02x | 0.07x |
| Net DebtTotal debt minus cash | -$69M | -$2.2B |
| Cash & Equiv.Liquid assets | $70M | $2.9B |
| Total DebtShort + long-term debt | $1M | $705M |
| Interest CoverageEBIT ÷ Interest expense | -816.06x | — |
EW leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
AVR leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AVR five years ago would be worth $11,750 today (with dividends reinvested), compared to $8,845 for EW. Over the past 12 months, AVR leads with a +50.2% total return vs EW's +7.1%. The 3-year compound annual growth rate (CAGR) favors AVR at 5.5% vs EW's -3.5% — a key indicator of consistent wealth creation.
| Metric | AVRAnteris Technolog… | EWEdwards Lifescien… |
|---|---|---|
| YTD ReturnYear-to-date | +33.7% | -6.3% |
| 1-Year ReturnPast 12 months | +50.2% | +7.1% |
| 3-Year ReturnCumulative with dividends | +17.5% | -10.2% |
| 5-Year ReturnCumulative with dividends | +17.5% | -11.5% |
| 10-Year ReturnCumulative with dividends | +17.5% | +125.5% |
| CAGR (3Y)Annualised 3-year return | +5.5% | -3.5% |
AVR leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — AVR and EW each lead in 1 of 2 comparable metrics.
Risk & Volatility
EW is the less volatile stock with a 0.64 beta — it tends to amplify market swings less than AVR's 2.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AVR currently trades 94.7% from its 52-week high vs EW's 91.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AVRAnteris Technolog… | EWEdwards Lifescien… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.14x | 0.64x |
| 52-Week HighHighest price in past year | $6.95 | $87.89 |
| 52-Week LowLowest price in past year | $2.85 | $72.30 |
| % of 52W HighCurrent price vs 52-week peak | +94.7% | +91.0% |
| RSI (14)Momentum oscillator 0–100 | 63.4 | 53.1 |
| Avg Volume (50D)Average daily shares traded | 800K | 4.7M |
Evenly matched — AVR and EW each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates AVR as "Buy" and EW as "Buy". Consensus price targets imply 128.0% upside for AVR (target: $15) vs 21.4% for EW (target: $97).
| Metric | AVRAnteris Technolog… | EWEdwards Lifescien… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $15.00 | $97.08 |
| # AnalystsCovering analysts | 1 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.9% |
Insufficient data to determine a leader in this category.
Key Takeaway
EW leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AVR leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Best OverallAnteris Technologies Global… (AVR)Leads 2 of 6 categories
Loading custom metrics...
AVR vs EW: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is AVR or EW a better buy right now?
For growth investors, Edwards Lifesciences Corporation (EW) is the stronger pick with 11.
5% revenue growth year-over-year, versus -1. 2% for Anteris Technologies Global Corp. (AVR). Edwards Lifesciences Corporation (EW) offers the better valuation at 43. 7x trailing P/E (26. 6x forward), making it the more compelling value choice. Analysts rate Anteris Technologies Global Corp. (AVR) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AVR or EW?
Over the past 5 years, Anteris Technologies Global Corp.
(AVR) delivered a total return of +17. 5%, compared to -11. 5% for Edwards Lifesciences Corporation (EW). Over 10 years, the gap is even starker: EW returned +125. 5% versus AVR's +17. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AVR or EW?
By beta (market sensitivity over 5 years), Edwards Lifesciences Corporation (EW) is the lower-risk stock at 0.
64β versus Anteris Technologies Global Corp. 's 2. 14β — meaning AVR is approximately 237% more volatile than EW relative to the S&P 500. On balance sheet safety, Anteris Technologies Global Corp. (AVR) carries a lower debt/equity ratio of 2% versus 7% for Edwards Lifesciences Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — AVR or EW?
By revenue growth (latest reported year), Edwards Lifesciences Corporation (EW) is pulling ahead at 11.
5% versus -1. 2% for Anteris Technologies Global Corp. (AVR). On earnings-per-share growth, the picture is similar: Edwards Lifesciences Corporation grew EPS -73. 7% year-over-year, compared to -194. 5% for Anteris Technologies Global Corp.. Over a 3-year CAGR, EW leads at 4. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AVR or EW?
Edwards Lifesciences Corporation (EW) is the more profitable company, earning 17.
7% net margin versus -28. 2% for Anteris Technologies Global Corp. — meaning it keeps 17. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EW leads at 27. 0% versus -29. 0% for AVR. At the gross margin level — before operating expenses — EW leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is AVR or EW more undervalued right now?
Analyst consensus price targets imply the most upside for AVR: 128.
0% to $15. 00.
07Which pays a better dividend — AVR or EW?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is AVR or EW better for a retirement portfolio?
For long-horizon retirement investors, Edwards Lifesciences Corporation (EW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
64), +125. 5% 10Y return). Anteris Technologies Global Corp. (AVR) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EW: +125. 5%, AVR: +17. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between AVR and EW?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(AVR: -44.2% · EW: 13.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.